Delicate to bringing novel medicines to cancer patients around the world

CANWELL BIOTECH Ltd., founded in June 2018, is an innovative drug research and development company, focusing  on the development and commercialization of anti-tumor First-in-Class and Best-in-Class immunotherapies. By harnessing both innate and adaptive immune responses against tumor cells. CanWell is building its immuno-oncology product platforms through 2 lead programs,  CAN1012, a TLR7 agonist, and DPV-001, a dendritic cell targeted cancer vaccine.